New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

Our Bureau, Mumbai Monday, May 12, 2025, 14:45 Hrs [IST] ...